Actively Recruiting

Age: 18Years +
All Genders
NCT05935605

Pulmonary Hypertension in Left Heart Disease

Led by Mayo Clinic · Updated on 2026-03-05

3000

Participants Needed

1

Research Sites

249 weeks

Total Duration

On this page

Sponsors

M

Mayo Clinic

Lead Sponsor

N

National Heart, Lung, and Blood Institute (NHLBI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.

CONDITIONS

Official Title

Pulmonary Hypertension in Left Heart Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients referred to the cardiac catheterization laboratory for invasive right heart catheterization for any reason.
  • Left Heart Disease, defined as one or more of the following:
  • Symptomatic HFpEF with normal left ventricular ejection fraction (≥50%) and objective evidence of heart failure.
  • Symptomatic HFrEF with reduced ejection fraction (<50%).
  • Symptomatic valvular heart disease with clinically significant aortic or mitral valve disease.
Not Eligible

You will not qualify if you...

  • Unable or unwilling to undergo noninvasive echocardiography or if it would compromise data quality.
  • Pulmonary arterial hypertension (Group 1 PH), hypoxia/lung disease-related PH (Group 3), thromboembolic PH (Group 4), or miscellaneous PH (Group 5).
  • Significant lung disease, hypoxemia, or lung infection.
  • Amyloid or infiltrative cardiomyopathy.
  • Acute myocarditis.
  • Acute coronary syndrome or revascularization within 90 days.
  • Use of pulmonary hypertension-specific drugs.
  • Constrictive pericarditis.
  • High output heart failure.
  • Heart failure hospitalization within 30 days.
  • Severe aortic or mitral valve stenosis.
  • Unable or unwilling to exercise.
  • Inadequate echocardiographic imaging windows.
  • Unable or unwilling to cooperate with breath holding.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

C

Circulatory Failure Research Team

CONTACT

B

Barry Borlaug, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Pulmonary Hypertension in Left Heart Disease | DecenTrialz